Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival in Major Trial, Now FDA-Approved

The pancreatic cancer drug daraxonrasib (brand name Rasonque) has become a significant new option for many Americans with advanced disease after the U.S. Food and Drug Administration approved it on August 26, 2026. This oral RAS inhibitor targets the mutations driving more than 90% of pancreatic ductal adenocarcinoma cases and produced clear survival gains versus chemotherapy in a large phase 3 trial.

What Is Daraxonrasib and How Does It Work?

Daraxonrasib is a first-in-class oral RAS(ON) multi-selective inhibitor developed by Revolution Medicines. It blocks active (GTP-bound) mutant and wild-type RAS proteins that fuel uncontrolled cell growth in the vast majority of pancreatic cancers. Unlike some earlier RAS-targeted drugs limited to specific mutations such as KRAS G12C, it addresses a broader range of RAS alterations common in this disease.

The recommended dose is 300 mg taken orally once daily until disease progression or unacceptable toxicity. It is taken as tablets and does not require a companion diagnostic test for RAS mutation status under the current approval.

FDA Approval Details and Who Qualifies

The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy. This covers the most common form of pancreatic cancer once it has spread and after initial treatment options have been exhausted or are unsuitable.

Approval rested on the phase 3 RASolute 302 trial, which enrolled 500 patients (about 92% with RAS G12 mutations) across multiple countries. Patients were randomized to daraxonrasib or investigator’s choice of standard chemotherapy. Full details appear in the FDA approval announcement.

Key Trial Results: Survival and Response Gains

In the overall study population, median overall survival reached 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (hazard ratio 0.40). Median progression-free survival was 7.2 months versus 3.6 months. Objective response rates were approximately 30–32% with the new drug compared with about 11% with chemotherapy.

These benefits held in the RAS G12 subgroup as well. Treatment discontinuation due to side effects was lower with daraxonrasib (1.2%) than with chemotherapy (11.2%). Patients also experienced slower worsening of pain and better preservation of quality of life measures. Results were published in the New England Journal of Medicine and presented at the 2026 ASCO meeting. Earlier phase 1/2 data that helped pave the way are summarized in coverage of daraxonrasib’s KRAS-targeting activity.

Side Effects and Safety Considerations

Common treatment-related effects include rash, diarrhea, nausea, stomatitis or mucositis, and fatigue. Most are grade 1 or 2 and manageable with supportive care; grade 3 or higher events occurred in roughly one-third of patients in earlier studies. Warnings in the prescribing information cover dermatologic toxicity, gastrointestinal issues (including perforation risk), interstitial lung disease/pneumonitis, and embryo-fetal toxicity. Patients should discuss monitoring and management strategies with their oncology team.

Cost, Access, and Practical Considerations for U.S. Patients

The wholesale acquisition cost is approximately $39,800 for a 30-day supply. Actual out-of-pocket costs vary widely depending on insurance type, formulary status, and eligibility for assistance. Revolution Medicines offers the (ON)Path patient support program, which may reduce costs to as little as $0 for some commercially insured patients who qualify. Medicare beneficiaries have additional protections under current Part D out-of-pocket limits, and other foundations may help with copays. Uninsured or underinsured patients meeting certain criteria may qualify for free drug through patient assistance.

Patients should contact their oncologist, specialty pharmacy, and insurance provider promptly after a prescription is written. Expanded access was available earlier in 2026 before full approval. Additional background on the trial outcomes and regulatory path is available in reporting on daraxonrasib’s phase 3 survival data.

Promising First-Line Data and What Comes Next

While the current approval is for previously treated or chemo-ineligible patients, early-phase results combining daraxonrasib with gemcitabine and nab-paclitaxel in treatment-naïve metastatic disease have shown encouraging signals. In a cohort of 61 patients, the confirmed objective response rate was about 61% (including complete responses in roughly 8%), with median progression-free survival of 12.8 months and a 12-month overall survival rate of 76.6%. These findings remain preliminary—they come from a non-randomized phase 1/2 study—and require confirmation. The ongoing phase 3 RASolute 303 trial is evaluating daraxonrasib alone or with chemotherapy versus chemotherapy alone in the first-line setting, regardless of RAS genotype. The FDA granted Breakthrough Therapy Designation to the combination in September 2026. Readers can follow broader pancreatic cancer resources from the Pancreatic Cancer Action Network.

What This Means for Patients and Families

For eligible patients whose disease has progressed after initial therapy, daraxonrasib offers a convenient oral alternative that has demonstrated longer survival and disease control than standard chemotherapy in a randomized trial. It is not a cure, and individual results vary. Oncologists will consider performance status, prior treatments, organ function, and overall goals of care when deciding whether it is appropriate.

Patients and caregivers should ask about molecular testing (though not required for this indication), clinical trial options such as RASolute 303 for first-line disease, supportive care resources, and financial counseling. Regular follow-up for side-effect management and imaging remains essential.

Have you or a loved one been affected by pancreatic cancer treatment decisions recently? Share your experiences or questions in the comments so others can benefit from the discussion.

Leave a Comment